Monitored anesthesia care (MAC) sedation: Clinical utility of fospropofol

Eric A. Harris, David Lubarsky, Keith A. Candiotti

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Fospropofol, a phosphorylated prodrug version of the popular induction agent propofol, is hydrolyzed in vivo to release active propofol, formaldehyde, and phosphate. Pharmacodynamic studies show fospropofol provides clinically useful sedation and EEG/bispectral index suppression while causing significantly less respiratory depression than propofol. Pain at the injection site, a common complaint with propofol, was not reported with fospropofol; the major patient complaint was transitory perianal itching during the drug's administration. Although many clinicians believe fospropofol can safely be given by a registered nurse, the FDA mandated that fospropofol, like propofol, must be used only in the presence of a trained anesthesia provider.

Original languageEnglish (US)
Pages (from-to)949-959
Number of pages11
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
StatePublished - Dec 1 2009
Externally publishedYes

Keywords

  • Fospropofol
  • Monitored anesthesia care
  • Propofol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'Monitored anesthesia care (MAC) sedation: Clinical utility of fospropofol'. Together they form a unique fingerprint.

  • Cite this